Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Dzankovic, F.
OUTCOMES OF HEART FAILURE THERAPY IN PATIENTS WITHOUT DIABETES TREATED WITH SGLT2-INHIBITORS
Humanmedizin; [ Diplomarbeit ] Medizinische Universität Graz; 2022. pp. 114
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Sourij Harald
- Altmetrics:
- Abstract:
- Introduction: Chronic heart failure poses a global disease with a prevalence of up to 2% in the general population. It comes with a high mortality rate, and is bound to a great financial burden, including extensive treatment costs. The pharmacological treatment of heart failure aims to improve the ejection fraction and lower the heart rate. Methods: This Diploma Thesis constitutes the result of Literature Research, using literature contained in Textbooks, different clinical studies and their reviews. Furthermore, the trial outcomes were accessed from research platform PubMed®. Results: The studies have shown that SGLT2-inhibitors have significant cardiac and metabolic benefits on patients with heart failure. Moreover, the benefits concerning weight, blood pressure, haematocrit, eGFR, and NT-proBNP were independent of diabetes status of patients. As a result of that, they are listed under guidelines for treatment of heart failure. The rate of adverse events did not differ significantly in those with and without diabetes. It is important to emphasize that significant hypoglycaemia or diabetic ketoacidosis did not present in any patient without diabetes at baseline. This is strong evidence that SGLT2-Inhibitors, instead as glucose-lowering drugs, should rather be used in cardioprotective therapy. Conclusion: Recently, SGLT2 inhibitors presented as promising therapy for patients with heart failure, with both reduced and preserved ejection fraction. Compelling data from clinical trials in people with heart failure, with or without diabetes, gave this class of drugs a prominent place in heart failure therapy. The studies exploring their renal impact are still ongoing.